Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

vantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.Orexigen.com.

Forward Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. For example, statements regarding the potential efficacy of Contrave(TM) may be forward looking statements. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Orexigen's business, including, without limitation: the results of this Phase IIb clinical trial and earlier clinical trials may not be predictive of future results; Orexigen's pending clinical trials may not proceed in the timeframes or in the manner Orexigen expects or at all; unexpected findings relating to Contrave(TM) or Empatic(TM) that could delay or prevent regulatory filings, approval or commercialization, or that could result in recalls or product liability claims; Orexigen and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in Orexigen's public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by t
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/25/2014)... 25, 2014  In today,s marketplace, launching multiple products ... - as is managing a portfolio of products in ... possible - or even preferable - to pool resources ... you combine resources and activities, and what marketing and ... are just a few of the dilemmas facing pharmaceutical ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... , SAN DIEGO, Nov. 18 Rules-Based ... biomarker alliance and services agreement with Covance Inc. (NYSE: ... with a powerful combination of biomarker technologies and services for ... will use RBM as its exclusive third-party provider of multiplexed ...
... , NASHVILLE, Tenn., Nov. 17 Emdeon (NYSE: ... cycle management solutions, today announced that it will participate in the ... 1 to 2, 2009 in New York. , The "fireside chat", ... time on Tuesday, December 1, 2009. A live audio webcast ...
Cached Medicine Technology:Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 At some point ... situation where they’re forced to contact the authorities. Distinguishing ... difficult than it initially seems. , Not every dangerous situation ... get stolen, a person get mugged, or a bank get ... obvious, leading onlookers to be more passive than they otherwise ...
(Date:7/28/2014)... University of Texas Health Science Center at San Antonio, the ... of pills that cures 9 of 10 hepatitis C patients. ... or without ribavirin, cured 93 percent of patients in 12 ... study published today in The Lancet . , ... Lawitz, M.D., clinical professor in the School of Medicine at ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... have a slightly increased risk of potentially fatal blood ... report. Doctors have previously suspected that babies born ... of deep vein thrombosis and pulmonary embolism, two serious ... researchers noted in background information. This new study ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3
... Consumer Watchdog sent a letter to Senator ... expressing their profound disappointment that consumer advocates had ... the Massachusetts senator to formulate health care reform ... recent national polls showing the public overwhelming opposed ...
... Results To Offer New Insights on How Well Asthma ... The American Lung Association of New England (ALANE) has ... offer an online survey and corresponding report that will ... being controlled and encourage them to discuss the results ...
... ROCKVILLE, Md., Feb. 20 /PRNewswire-Asia/ -- Synutra,International, ... a leading infant formula,company in China, and ... products,for infants, children and adults, today issued ... permit numbers in a published list of ...
... eFoodSafety.com, Inc., (OTC Bulletin Board: EFSF) an emerging ... aesthetics, dermatology, environmental and nutraceutical products, outlined its ... 30, 2010 during its regularly scheduled monthly investor ... eFoodSafety.com intends to increase revenues by improving the ...
... Many people seek answers to questions of motivation and ... by Justin Honaman employs lessons learned in his career ... an effort to help others direct their energies and ... chapters of "Make It Happen" that personal branding is ...
... the world,s largest autism science and advocacy organization, is teaming up ... series "Wow! Wow! Wubbzy!" - to promote World Autism Awareness Day ... autism as a worldwide health crisis. , ... New ...
Cached Medicine News:Health News:Consumer Watchdog to U.S. Senate: Don't Leave Consumers Out of Health Reform Debate, Public Opposes Mandatory Purchases of Private Insurance & Supports Opening Medicare to Everyone 2Health News:American Lung Association of New England Launches Online Asthma Control Test 2Health News:American Lung Association of New England Launches Online Asthma Control Test 3Health News:American Lung Association of New England Launches Online Asthma Control Test 4Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 2Health News:Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification 3Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 2Health News:eFoodSafety.com Provides Revenue Guidance for FY 2010 3Health News:Business Strategist Applies Corporate Experience to Self-Help: 'Make It Happen' 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 2Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 3Health News:Autism Speaks and 'Wow! Wow! Wubbzy!' Team Up to Shine a Spotlight on World Autism Awareness Day 4
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: